H. Parker

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

C3 Jian, Inc. operates as a biotechnological research and development company. It provides development and commercialization of pathogen-specific and antimicrobials that treat and prevent diseases caused by microbial dysbiosis. The company is headquartered in Marina del Rey, CA.

Part of Amgen, Inc., Receptech Corp. is a company that sells Immunex products. The company is based in Seattle, WA. Receptech was acquired by Immunex Corp., part of Amgen, Inc. from July 16, 2002 on December 16, 1992 for $59.40 million.

Nexgenia, Inc. develops molecule-specific selection reagents. Its technology include polymer-protein conjugates and magnetic nanoparticles. The company was founded by James Lai and Thomas Schulte in February 2011 and is headquartered in Seattle, WA.

Global Partnerships invests in partnerships with local organizations that use market-based solutions for people living in poverty. The firm invests in the areas such as health services, rural livelihoods, green technology and microentrepreneurship. The company was founded by Paula Clapp and Bill Clapp in 1994 and is headquartered in Seattle, WA.

C3J Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of novel targeted antimicrobials-synthetic bacteriophage and antimicrobial peptides. The company was founded by Randal Eckert, Maxwell H. Anderson and Wenyuan Shi in 2005 and is headquartered in Marina del Rey, CA.

Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC.

OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Inventprise LLC is a private company that is developing vaccines against infectious diseases, with a focus on invasive pneumococcal disease, using their innovative platform technology. The company is based in Redmond, WA. The company also offers contract services in biologics, including process development, optimization, analytical services, and manufacturing from early clinical trials through commercialization. The company was founded by Subhash Vinayak Kapre, who has been the CEO since incorporation.